Intellia Therapeutics Shares Plunge Following FDA Clinical Hold

A severe clinical setback has struck Intellia Therapeutics, sending its stock value tumbling after the U.S. Food and Drug Administration (FDA) imposed a full stop on its pivotal programs. This regulatory action was triggered by a patient death reported in a key Phase 3 trial, creating immense uncertainty for investors regarding the safety of the company’s technology and the future of its lead drug candidate.

The immediate cause for the stock’s decline is an FDA-mandated “Clinical Hold” on the MAGNITUDE studies for the investigational drug, Nex-z. The hold was instituted following a serious adverse event report detailing a patient fatality linked to acute liver failure accompanied by Read more...